4D Molecular Therapeutics (FDMT) Equity Ratio (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Equity Ratio data on file, last reported at 0.88 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.88, down 3.28% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.88 (down 3.28% YoY), and the FY2025 annual result was 0.89, down 2.07% from the prior year.
• Equity Ratio eased to 0.88 in Q1 2026 per FDMT's latest filing, from 0.89 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.95 in Q1 2024 and troughed at 0.87 in Q3 2025.
• A 5-year average of 0.91 and a median of 0.91 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio climbed 6.43% in 2024, then retreated 6.34% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.88 in 2022, then grew by 2.51% to 0.91 in 2023, then grew by 0.61% to 0.91 in 2024, then fell by 2.07% to 0.89 in 2025, then decreased by 1.27% to 0.88 in 2026.
• Business Quant data shows FDMT's Equity Ratio at 0.88 in Q1 2026, 0.89 in Q4 2025, and 0.87 in Q3 2025.